Major challenges for gene therapy of thalassemia and sickle cell disease

Current Gene Therapy

Volumn 10, Issue 5, 2010, Pages 404-412

  Papanikolaou, Eleni ^a,b   Anagnou, Nicholas P ^a,b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bone marrow; Gene therapy; Hematopoietic stem cells (hHSCs); Hemoglobinopathies; HPFH; Lentiviral vector; Sickle cell disease; Thalassemia

Indexed keywords

BETA GLOBIN; ENVELOPE PROTEIN; GAMMA GLOBIN; HEMOGLOBIN F; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

BETA THALASSEMIA; CD34+ T LYMPHOCYTE; GENE SILENCING; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HUMAN; REVIEW; SICKLE CELL ANEMIA; T LYMPHOCYTE; THALASSEMIA; TRANSGENE;

VESICULAR STOMATITIS VIRUS;

EID: 78651338767     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310793180724     Document Type: Review

References (76)

1. Flint J, Harding RM, Boyce AJ and Clegg JB. The populationgenetics of the hemoglobinopathies. In: GP Rodgers, Ed. Bailliere's Clinical Haematology. London: Bailliere Tindall 1998; pp. 1-52.
2. Weatherall DJ, Clegg JB. Thalassemia-a global public healthproblem. Nat Med 1996; 2: 847-49.
3. Weatherall DJ. The thalassemias. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H, Eds. The Molecular Basisof Blood Diseases, 3rd ed. Philadelphia: Saunders 2001; pp 183-26.
4. Weatherall DJ. Pathophysiology of thalassemia. In: GP Rodgers, Ed. Bailliere's Clinical Haematology. London: Bailliere Tindall; 1998; pp. 127-46.
5. Orkin S, Nathan D. The thalassemias. In: Orkin S, Nathan D, Eds. Nathan and Oski's Hematology of Infancy and Childhood, 5th ed. Philadelphia: Saunders 1998; pp. 811-86.
6. Mathias LA, Fisher TC, Zeng L, et al. Ineffective erythropoiesis in β-thalassemia major is due to apoptosis at the polychromatophilicnormoblast stage. Exp Hem 2000; 28: 1343-53.
7. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81: 858-63.
8. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle celldisease. Life expectancy and risk factors for early death. N Engl JMed 1994; 330: 1639-44.
9. Davis H, Schoendorf KC, Gergen PJ, Moore RM, Jr. Nationaltrends in the mortality of children with sickle cell disease, 1968through 1992. Am J Public Health 1997; 87: 1317-22.
10. http://www.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf. Fifty-Ninth World Health Assembly, Provisional Agenda Item11.4. World Health Organization. 2006; A59: 1.
11. Weatherall DJ, Clegg JB. The thalassemia syndromes. Oxford:Blackwell Science 2001; pp. 25-32.
12. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival andcomplications in patients with thalassemia major treated with transfusionand deferoxamine. Haematologica 2004; 89: 1187-93.
13. Walters MC, Patience M, Leisenring W, et al. Barriers to bonemarrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996; 2: 100-04.
14. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoieticstem-cell transplantation for sickle cell disease. N Engl JMed 2009; 361: 2309-17.
15. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of relatedmyeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110: 2749-56.
16. Fleischhauer K, Locatelli F, Zecca M, et al. Graft rejection afterunrelated donor hematopoietic stem cell transplantation for thalassemiais associated with nonpermissive HLA-DPB1 disparity inhost-versus-graft direction. Blood 2006; 107: 2984-92.
17. Andreani M, Testi M, Battarra M, et al. Relationship betweenmixed chimerism and rejection after bone marrow transplantationin thalassemia. Blood Transfus 2008; 6: 143-9.
18. Bulger M, van Doorninck JH, Saitoh N, et al. Conservation ofsequence and structure flanking the mouse and human β-globinloci: the β-globin genes are embedded within an array of odorantreceptor genes. Proc Natl Acad Sci USA 1999; 96: 5129-34.
19. Bulger M, Bender MA, van Doorninck JH, et al. Comparativestructural and functional analysis of the olfactory receptor genesflanking the human and mouse β-globin gene clusters. Proc Natl Acad Sci USA 2000; 97: 14560-5.
20. Forget BG. Molecular mechanisms of β-thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, Eds. Disorders of hemoglobin:genetics, pathophysiology, and clinical management. Cambridge UK: Cambridge University Press 2001; pp. 252-276.
21. Viprakasit V, Tanphaichitr VS, Chinchang W, Sangkla P, Weiss MJ, Higgs DR. Evaluation of alpha hemoglobin stabi-lizing protein(AHSP) as a genetic modifier in patients with β-thalassemia. Blood 2004; 103: 3296-99.
22. Yu C, Niakan KK, Matsushita M, Stamatoyannopoulos G, Orkin SH, Raskind WH. X-linked thrombocytopenia with thalassemiafrom a mutation in the amino finger of GATA-1 affecting DNAbinding rather than FOG-1 interaction. Blood 2002; 100: 2040-45.
23. Forrester WC, Epner E, Driscoll MC, et al. A deletion of the human β-globin locus activation region causes a major alteration inchromatin structure and replication across the entire β-globin locus. Genes Dev 1990; 4: 1637-49.
24. Anagnou NP, Perez-Stable C, Gelinas R, et al. Sequences located 3' to the breakpoint of the hereditary persistence of fetal hemoglobin-3 deletion exhibit enhancer activity and can modify the developmental expression of the human fetal A gamma-globin gene in transgenic mice. J Biol Chem 1995; 270: 10256-63.
25. Tuan D, Feingold E, Newman M, Weissman SM, Forget BG. Different3' end points of deletions causing δ β-thalassemia and hereditarypersistence of fetal hemoglobin: implications for the controlof gamma-globin gene expression in man. Proc Natl Acad Sci USA 1983; 80: 6937-41.
26. Thein SL. Genetic insights into the clinical diversity of β-thalassemia. Br J Haematol 2004; 124: 264-74.
27. Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol 2002; 9: 123-6.
28. Bunn FH. Human hemoglobins: sickle hemoglobin and other mutants. In: Stamatoyannopoulos G, Majerus PW, Pelmutter RM, Varmus H, Eds. The molecular basis of blood diseases, 2nd ed. Philadelphia: Saunders 2001; pp. 183-226.
29. Quek L and Thein SL. Molecular therapies in b-thalassemia. Br JHaematol 2006; 136: 353-65.
30. Williams DA, Lemischka IR, Nathan DG, Mulligan RC. Introductionof new genetic material into pluripotent haematopoietic stemcells of the mouse. Nature 1984; 310: 476-80.
31. Dzierzak EA, Papayannopoulou T, Mulligan RC. Lineage-specificexpression of a human β-globin gene in murine bone marrow transplantrecipients reconstituted with retrovirus-transduced stem cells. Nature 1988; 331: 35-41.
32. Karlsson S, Bodine DM, Perry L, Papayannopoulou T, Nienhuis AW. Expression of the human β-globin gene following retroviralmediated transfer into multipotential hematopoietic progenitors ofmice. Proc Natl Acad Sci USA 1988; 85: 6062-66.
33. Bender MA, Gelinas RE, Miller AD. A majority of mice show longterm expression of a human β-globin gene after retrovirus transferinto hematopoietic stem cells. Mol Cell Biol 1989; 9: 1426-34.
34. Tuan D, London IM. Mapping of DNase I-hypersensitive sites inthe upstream DNA of human embryonic β-globin gene in K562leukemia cells. Proc Natl Acad Sci USA 1984; 81: 2718-22.
35. Forrester WC, Novak U, Gelinas R, Groudine M. Molecular analysisof the human β-globin locus activation region. Proc Natl Acad Sci USA 1989; 86: 5439-43.
36. Novak U, Harris EA, Forrester W, Groudine M, Gelinas R. Highlevel β-globin expression after retroviral transfer of locus activationregion-containing human β-globin gene derivatives into murineerythroleukemia cells. Proc Natl Acad Sci USA 1990; 87: 3386-90.
37. May C, Rivella S, Callegari J, et al. Therapeutic hemoglobin synthesisin β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 2000; 406: 82-86.
38. Imren S, Payen E, Westerman KA, et al. Permanent and panerythroidcorrection of murine β-thalassemia by multiple lentiviralintegration in hematopoietic stem cells. Proc Natl Acad Sci USA 2002; 99: 14380-85.
39. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sicklecell disease in transgenic mouse models by gene therapy. Science 2001; 294: 2368-71.
40. Miccio A, Cesari R, Lotti F, et al. In vivo selection of geneticallymodified erythroblastic progenitors leads to long-term correction of β-thalassemia. Proc Natl Acad Sci USA 2008; 105: 10547-52.
41. Hanawa H, Hargrove PW, Kepes S, Srivastava DK, Nienhuis AW, Persons DA. Extended β-globin locus control region elements promoteconsistent therapeutic expression of a gamma-globin lentiviralvector in murine β-thalassemia. Blood 2004; 104: 2281-90.
42. Noronha PA, Vida LN, Park CL, Honig GR. Hemoglobin-specificantibody in a multiply transfused patient with sickle cell disease. Blood 1997; 89: 2155-58.
43. Bunn HF. Induction of fetal hemoglobin in sickle cell disease. Blood 1999; 93: 1787-89.
44. Emery DW, Yannaki E, Tubb J, Nishino T, Li Q, Stamatoyannopoulos G. Development of virus vectors for gene therapy of βchain hemoglobinopathies: Flanking with a chromatin insulator reduces γ-globin gene silencing in vivo. Blood 2002; 100: 2012-19.
45. Persons DA, Hargrove PW, Allay ER, Hanawa H, Nienhuis AW. The degree of phenotypic correction of murine β-thalassemia intermediafollowing lentiviral-mediated transfer of a human γ-globingene is influenced by chromosomal position effects and vectorcopy number. Blood 2003; 101: 2175-83.
46. Papanikolaou E, Georgomanoli M, Anagnou NP. New Lentiviral Vectors for Gene Therapy of Thalassemia with the HPFH-2 Enhancerand the-117 HPFH Activating Mutation: Studies on Thalassemic Hematopoietic Stem Cells. Mol Ther 16 (Suppl. 1) 2008; S278.
47. Perumbeti A, Higashimoto T, Urbinati F, et al. A novel humangamma-globin gene vector for genetic correction of sickle cellanemia in a humanized sickle mouse model: critical determinantsfor successful correction. Blood 2009; 114: 1174-85.
48. Imren S, Fabry ME, Westerman KA, Pawliuk R, Tang P, Rosten PM. High-level β-globin expression and preferred intragenic integrationafter lentiviral transduction of human cord blood stem cells. J Clin Invest 2004; 114: 953-62.
49. Puthenveetil G, Scholes J, Carbonell D, et al. Successful correctionof the human β-thalassemia major phenotype using a lentiviral vector. Blood 2004; 104: 3445-53.
50. Rivella S, May C, Chadburn A, Riviere I, Sadelain M. A novelmurine model of Cooley anemia and its rescue by lentiviralmediatedhuman β-globin gene transfer. Blood 2003; 101: 2932-39.
51. Baum C. What are the consequences of the fourth case? Mol Ther 2007; 15: 1401-2.
52. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T-cell proliferation in 2 patients after gene therapyfor SCID-X1. Science 2003; 302: 415-9.
53. Check E. Gene therapy put on hold as third child develops cancer. Nature 2005; 433: 561.
54. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemiafollowing gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3: 477-88.
55. Arumugam PI, Scholes J, Perelman N, Xia P, Yee JK, Malik P. Improved human β-globin expression from self-inactivating lentiviralvectors carrying the chicken hypersensitive site-4 (cHS4) insulatorelement. Mol Ther 2007; 15: 1863-71.
56. Urbinati F, Arumugam P, Higashimoto T, et al. Mechanism ofreduction in titers from lentivirus vectors carrying large inserts inthe 3'LTR. Mol Ther 2009; 17: 1527-36.
57. Fragkos M, Anagnou NP, Tubb J, Emery DW. Use of the hereditarypersistence of fetal hemoglobin 2 enhancer to increase the expressionof oncoretrovirus vectors for human γ-globin. Gene Ther 2005; 12: 1591-1600.
58. Aker M, Tubb J, Groth AC, et al. Extended core sequences fromthe cHS4 insulator are necessary for protecting retroviral vectorsfrom silencing position effects. Hum Gene Ther 2007; 18: 333-43.
59. Arumugam PI, Urbinati F, Velu CS, Higashimoto T, Grimes HL, Malik P. The 3' region of the chicken hypersensitive site-4 insulatorhas properties similar to its core and is required for full insulatoractivity. PLo S One 2009; 4: e6995.
60. Li CL, Xiong D, Stamatoyannopoulos G, Emery DW. Genomicand functional assays demonstrate reduced gammaretroviral vectorgenotoxicity associated with use of the cHS4 chromatin insulator. Mol Ther 2009; 17: 716-24.
61. Arumugam PI, Higashimoto T, Urbinati F, et al. Genotoxic potentialof lineage-specific lentivirus vectors carrying the β-globin locuscontrol region. Mol Ther 2009; 17: 1929-37.
62. Hargrove PW, Kepes S, Hanawa H, et al. Globin lentiviral vectorinsertions can perturb the expression of endogenous genes in β-thalassemic hematopoietic cells. Mol Ther 2008; 16: 525-33.
63. Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery andstable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7.
64. Case SS, Price MA, Jordan CT, et al. Stable transduction of quiescentCD34(+)CD38(-) human hematopoietic cells by HIV-1-basedlentiviral vectors. Proc Natl Acad Sci USA 1999; 96: 2988-93.
65. Persons DA, Allay ER, Sawai N, et al. Successful treatment ofmurine β-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 2003; 102: 506-13.
66. Zhao H, Pestina TI, Nasimuzzaman M, Mehta P, Hargrove PW, Persons DA. Amelioration of murine β-thalassemia through drugselection of hematopoietic stem cells transduced with a lentiviralvector encoding both gamma-globin and the MGMT drugresistancegene. Blood 2009; 113: 5747-56.
67. Larochelle A, Choi U, Shou Y, et al. In vivo selection of hematopoieticprogenitor cells and temozolomide dose intensification inrhesus macaques through lentiviral transduction with a drug resistancegene. J Clin Invest 2009; 119: 1952-63.
68. Verhoeyen E, Wiznerowicz M, Olivier D, et al. Novel lentiviralvectors displaying "earlyacting cytokines" selectively promote survivaland transduction of NOD/SCID repopulating human hematopoieticstem cells. Blood 2005; 106: 3386-95.
69. Ghani K, Wang X, de Campos-Lima PO, et al. Efficient humanhematopoietic cell transduction using RD114-and GALVpseudotypedretroviral vectors produced in suspension and serumfreemedia. Hum Gene Ther 2009; 20: 966-74.
70. Neff T, Peterson LJ, Morris JC, et al. Efficient gene transfer tohematopoietic repopulating cells using concentrated RD114-pseudotype vectors produced by human packaging cells. Mol Ther 2004; 9: 157-9.
71. http://www.esh.org/ChaptersIron HB/IRON2009_CAP.15(390-401).pdf. Payen E, Nègre O, Gillet-Legrand B, Beuzard Y, Gluckman E, Leboulch P. The European School of Haematology (ESH). THE HANDBOOK 2009 EDITION. CHAPTER 15: pp. 390-401.
72. Kaiser J. β-Thalassemia treatment succeds, with a caveat. Science 2009; 326: 1468-9.
73. http://oba.od.hih.gov.oba/RAC/meetings/dec 2008/RAC_Minutes_12-08.pdf; http://oba.od.hih.gov. oba/RAC/meetings/mar 2009/March%202009%20minutes. pdf
74. Persons D. Hematopoietic stem cell gene transfer for the treatmentof hemoglobin disorders. Hematol Am Soc Hematol Educ Prog 2009; 690-697.
75. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cellanemia mouse model with iPS cells generated from autologousskin. Science 2007; 318: 1920-3.
76. Ye L, Chang JC, Lin C, Sun X, Yu J, Kan YW. Induced pluripotentstem cells offer new approach to therapy in thalassemia and sicklecell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci USA 2009; 106: 9826-30.